Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.
作者信息
Dermime Said, Merhi Maysaloun, Merghoub Taha
机构信息
National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Translational Cancer Research Facility, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
出版信息
Front Immunol. 2021 Oct 21;12:781872. doi: 10.3389/fimmu.2021.781872. eCollection 2021.
Abstract
摘要
相似文献
1
Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.社论：癌症中抗免疫检查点抑制剂反应的动态生物标志物
Front Immunol. 2021 Oct 21;12:781872. doi: 10.3389/fimmu.2021.781872. eCollection 2021.
2
Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.免疫检查点抑制剂相关毒性的预测生物标志物。
Front Immunol. 2020 Oct 6;11:2023. doi: 10.3389/fimmu.2020.02023. eCollection 2020.
3
The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series).免疫检查点抑制剂在间变性甲状腺癌中的作用（病例系列）。
Oral Oncol. 2020 Oct;109:104744. doi: 10.1016/j.oraloncology.2020.104744. Epub 2020 May 10.
4
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1.针对程序性死亡 1 和程序性死亡配体 1 的免疫检查点治疗的生物标志物。
Biomed Pharmacother. 2020 Oct;130:110621. doi: 10.1016/j.biopha.2020.110621. Epub 2020 Sep 2.
5
Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review.免疫检查点抑制剂在罕见肿瘤中的疗效：系统评价。
Front Immunol. 2021 Sep 20;12:720748. doi: 10.3389/fimmu.2021.720748. eCollection 2021.
6
Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.原发灶与配对转移灶肿瘤中免疫治疗反应预测生物标志物的不一致性：系统评价和荟萃分析。
EBioMedicine. 2021 Jan;63:103137. doi: 10.1016/j.ebiom.2020.103137. Epub 2020 Dec 11.
7
Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.免疫检查点阻断治疗的分子谱与年龄相关的差异。
Front Immunol. 2021 Apr 15;12:657575. doi: 10.3389/fimmu.2021.657575. eCollection 2021.
8
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.PD-1/PDL-1 阻断在癌症免疫治疗中的现状和未来展望。
J Immunol Res. 2021 Feb 22;2021:6661406. doi: 10.1155/2021/6661406. eCollection 2021.
9
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.隐匿于黑暗之中：CD40 在免疫检查点阻断治疗中的表达及临床相关性的泛癌特征分析。
Mol Cancer. 2021 Nov 10;20(1):146. doi: 10.1186/s12943-021-01442-3.
10
Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.免疫检查点抑制剂在胆管癌治疗中的应用。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211039952. doi: 10.1177/15330338211039952.
引用本文的文献
1
Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.血清免疫介质作为高组织 PD-L1 表达的非小细胞肺癌患者对抗 PD-1/PD-L1 治疗反应的新型预测因子。
Front Immunol. 2023 May 15;14:1157100. doi: 10.3389/fimmu.2023.1157100. eCollection 2023.
2
Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.地西他滨治疗诱导结直肠癌细胞干性标志物、PD-L1 和 NY-ESO-1 的表达：联合化疗免疫治疗的潜力。
J Transl Med. 2023 Mar 31;21(1):235. doi: 10.1186/s12967-023-04073-y.
3
Bioinformatics analysis of the prognostic and immunotherapeutic significance of NPRL2 in stomach adenocarcinoma.NPRL2在胃腺癌中的预后及免疫治疗意义的生物信息学分析
J Gastrointest Oncol. 2022 Aug;13(4):1589-1604. doi: 10.21037/jgo-22-115.
本文引用的文献
1
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.PD-1 和 CTLA-4 阻断治疗反应和耐药的新兴动力学途径：通过应对复杂性来解决不确定性。
J Exp Clin Cancer Res. 2021 Feb 18;40(1):74. doi: 10.1186/s13046-021-01872-3.
2
Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.一名转移性胃癌患者接受联合放射免疫治疗后获益，其体内存在持续的抗 NY-ESO-1 特异性 T 细胞和表达差异生物标志物：一例报告。
J Immunother Cancer. 2020 Sep;8(2). doi: 10.1136/jitc-2020-001278.
3
Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.头颈部鳞状细胞癌对程序性细胞死亡蛋白-1 靶向治疗的反应及免疫标志物的差异表达：一例报告。
Front Immunol. 2018 Jul 30;9:1769. doi: 10.3389/fimmu.2018.01769. eCollection 2018.
4
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的总生存期
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
5
Pembrolizumab versus Ipilimumab in Advanced Melanoma.帕博利珠单抗对比伊匹单抗用于晚期黑色素瘤。
N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.
6
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.在接受伊匹单抗治疗的晚期黑色素瘤患者中，NY-ESO-1 抗体和 CD8+ T 细胞反应的综合与临床获益相关。
Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16723-8. doi: 10.1073/pnas.1110814108. Epub 2011 Sep 20.
Zotero 插件